|
|
||||||||
1 Department of Community & Family Medicine, Dartmouth Medical School, Lebanon, NH
2 Department of Family Medicine, Oregon Health & Science University School of Medicine, Portland, Ore
3 Department of Radiology, Dartmouth Medical School, Lebanon, NH
4 Department of Medicine, Dartmouth Medical School, Lebanon, NH
CORRESPONDING AUTHOR: Patricia A. Carney, PhD, Department of Family Medicine, Oregon Health and Science University, Sam Jackson Rd Mail Code: FM, Portland, OR 97239, carneyp{at}ohsu.edu
| ABSTRACT |
|---|
|
|
|---|
METHODS Using population-based mammography registry data from 20002002, we identified 143 women with interval breast cancers and 481 women with screen-detected breast cancers. We surveyed womens primary care clinicians to assess how the interval breast cancers were found and factors associated with their discovery.
RESULTS Women with interval cancers were twice as likely to have a personal history of breast cancer (30.1%) as women with screen-detected cancers (13.6%). Among women with interval cancers, one half of the invasive tumors (49.5%) were discovered when women initiated a health care visit because of a breast concern, and 16.8% were discovered when a clinician found an area of concern while conducting a routine clinical breast examination. Having a lump and both a personal and a family history of breast cancer was the most common reason why women initiated a health care visit (44%) (P <.01).
CONCLUSIONS Women with interval cancers are most likely to initiate a visit to a primary care clinician when they have 2 or more breast concerns. These concerns are most likely to include having a lump and a personal and/or family history of breast cancer. Women at highest risk for breast cancer may need closer surveillance by their primary care clinicians and may benefit from a strong educational message to come for a visit as soon as they find a lump.
Key Words: Mammography screening breast neoplasms community health public health signs symptoms surveillance health care seeking behavior
| INTRODUCTION |
|---|
|
|
|---|
Little attention has been paid to how interval breast cancers are ultimately discovered. Women undergoing routine clinical breast examinations and screening mammography who receive a report of normal findings may be unlikely to conduct routine breast self-examination. Given the US Preventive Services Task Force does not recommend breast self-examination because of lack of evidence on its effectiveness,11 primary care clinicians might not recommend this screening activity to their patients. We conducted an observational study of 143 women with interval breast cancers to determine how their cancers were discovered, and we assessed factors associated with discovery. We hypothesized that interval cancers would be discovered equally (1) by women with a breast cancer concern initiating a health care visit, (2) by the womens primary care clinician finding a breast problem during a routine health maintenance visit, or (3) by the next screening (for the purposes of our study, we defined this as the examination following within 365 days of the initial screening mammogram interpreted as normal). We further hypothesized that interval cancer discovery would be influenced by the patients age, education, relationship with her health care professional, and tumor size, which may additionally be affected by the time interval between the initial screening mammogram and the date of diagnosis.
| METHODS |
|---|
|
|
|---|
Data collection procedures associated with the NHMN have been approved by the Committee for the Protection of Human Subjects at Dartmouth College. These data include demographic, risk factor, and health history information (obtained through a self-administered questionnaire); history of previous breast procedures (eg, breast reduction, implants, biopsy, surgery, radiation therapy); personal history of breast cancer and family history of breast cancer (ie, occurrence in a first-degree relative); menopausal status and current use of hormone replacement therapy (HRT) (obtained in a face-to-face interview by the radiology technician); and breast density, mammographic interpretation, and follow-up recommendations assessed by the radiologist using the Breast Imaging Reporting and Data System (BI-RADS) categories of the American College of Radiology (ACR).13 Benign and malignant pathology data are collected from participating pathology laboratories, and breast cancer cases are routinely supplemented by the New Hampshire State Cancer Registry for capture of cancers in New Hampshire that bypassed pathology laboratories. The ascertainment, linking, and coding of pathology data are also described in more detail elsewhere.12
Procedures for Interval Cancer Discovery Study
We identified 624 women with a diagnosis of breast cancer within the study period (20002002). A total of 481 (77%) of the women had a screen-detected cancer, which was defined as a cancer diagnosed within 90 days of a bilateral screening mammogram interpreted as abnormal using BI-RADS categories 0 (needs additional assessment), 4 (suspicious abnormality), and 5 (highly suggestive of malignancy).13 A total of 143 (23%) of the women had an interval cancer, which was defined as a cancer diagnosed within 365 days of a bilateral screening mammogram that was interpreted as normal using BI-RADS category 1 (negative), category 2 (benign finding with routine follow-up recommended), and category 3 (short-interval follow-up).13
We obtained the womens demographic and risk information from the NHMN database and identified the primary care clinician who recommended the original screening mammogram associated with detection of the interval cancers. We developed and pilot-tested a data collection instrument to be completed only by the health care clinicians of the women with interval cancers. The instrument determined the patients status in the practice, how their breast cancer was discovered, the actions taken and dates of events after the breast cancer was found, patient breast concerns known to the clinicians, and patient outcomes as of December 31, 2003.
To pilot-test the data collection form, we asked several primary care clinicians (2 family physicians, 1 internist, and 1 nurse-practitioner) to review the form and attempt to complete it for designated patients. We conducted cognitive interviews to revise the instrument until it could be accurately and consistently completed. The data collection form was then mailed to the primary care clinicians of women with interval cancers. A second mailing was undertaken within 3 weeks of the first if no response was received. Of the 143 forms mailed to primary care clinicians, 101 forms (70.6%) were completed, 22 (15.4%) were partially completed, and 20 (14.0%) were not returned, even after 2 mailed attempts.
For some aspects of our study, it was important to compare the characteristics of the women and tumors according to the mechanism of cancer detection (screen-detected vs interval cancers). We created an analytic file with the characteristics of all women receiving a diagnosis of breast cancer during the study period and compared characteristics between women with screen-detected cancers and women with interval cancers. Descriptive statistics were calculated for both continuous and categorical data. Continuous data were compared using the t test, and categorical data were compared using the Fisher exact test.14 All tests were 2-tailed with
set at .05. For main analyses, only the 101 women with complete data were included. The strengths and weaknesses of this approach are debated in the Discussion below.
| RESULTS |
|---|
|
|
|---|
|
|
The 101 women with interval cancers included in our main analyses had a total of 229 breast concerns (Table 2
). The most common concerns were a personal and/or family history of breast cancer and a lump in the breast. Less frequent concerns included skin changes. The 22 concerns in the "other" category included pain or tenderness (n = 6), a problem that had developed in an area of a breast where a previous mammogram had detected a benign abnormality (n = 5), other concerns (n = 7), and no concerns (n = 4) (data not shown). The type of concern did not differ by patient age except for concerns about a breast lump: younger women tended to be more likely than their older counterparts to have lumps.
|
|
| DISCUSSION |
|---|
|
|
|---|
Women with invasive interval cancers had larger tumors, had higher stages and grades of breast cancer, and were more likely to have positive lymph nodes than their counterparts with invasive screen-detected cancers. Invasive interval cancers were found about 200 days after the initial screening mammogram, which was approximately 1 month later than in situ interval disease was discovered. This is surprising because in situ disease is often not palpable. We were also surprised to find no differences by age in breast cancer discovery scenario, total number of symptoms or concerns, or cluster of concerns. We had hypothesized that older women would be less likely to detect a lump themselves and initiate a health care visit. Younger womens breasts are often more nodular, which would make detecting a lump more difficult.
Women with interval cancers were much more likely to have a personal history of breast cancer when compared with women with screen-detected cancers. Although conducting breast self-examination has not been found to reduce breast cancer mortality and is not recommended by the US Preventive Services Task Force11 as a routine screening procedure for the general public, perhaps it should be recommended for women at high risk for breast cancer, such as those with a personal or family history of the disease. Additional research is needed in this area; however, a randomized trial may be difficult to conduct because of ethical concerns. Although it is recommended that women with a family history of breast cancer start mammography screening at a younger age, there is no specific recommendation for a screening interval different from that for women in general.11 A recent study on the efficacy of breast cancer screening among women at high risk (defined as having a positive family history and a previous breast biopsy) vs average risk (defined as having a negative family history and no previous breast biopsy) found a modest, though not significant association between screening and reduced mortality among women at high risk (odds ratio = 0.74, 95% confidence interval, 0.501.03).17 This finding further suggests the importance of educating high-risk women about the need to see their clinicians if they find an abnormality.
Previous screening history (before the screening mammogram linked to the interval or screen-detected cancer) also differed between women with screen-detected vs interval cancers. Women with screen-detected cancers were more likely to have their cancer found by the first mammogram they had ever had. No differences were noted by age, education, breast density, family history of breast cancer, menopausal status and use of HRT, or time since last clinical breast examination. We found surprising the lack of difference by breast density and by menopausal status and HRT use, as many studies have found these factors to be associated with difficulty in detecting breast cancer.1821 Although insurance status differed significantly between women with screen-detected cancer and women with interval cancers, it is unclear whether the difference between the proportions with insurance (96% vs 99%, respectively) is clinically relevant.
When we assessed patient status in the practice among the women with interval cancers who had the most common breast concerns, we found that most of these women were currently cared for by the health care clinician who had referred them for the mammogram that detected their interval cancer. An important relationship with a primary care physician was thus the primary model of health care for the majority of women in the study. Although we do not know how long the relationship had been established, it is likely an important one for detection of interval cancers. Our data indicate that the interval cancers found were generally more aggressive than the screen-detected cancers, which underscores the importance of surveillance for high-risk women. Previous research has shown that between 70% and 85% of interval cancers are not mammographically detectable58 but are growing rapidly. Initiating a health care visit when an abnormality is found may help to identify these rapidly growing cancers when long-term survival is still possible.
Our study was conducted among a population-based sample of women undergoing mammography screening, which has both strengths and limitations. A strength is that we were able to identify women with interval cancers for study and, with the help of their primary care clinicians, we were able to obtain information on how their interval cancers were found, a topic that has received little attention in the breast cancer surveillance literature. Our study, however, is only generalizable to women in northern New England who obtained mammograms. Additional research is needed to confirm our findings. A limitation is that many of our analyses were based only on the 101 women for whom we had complete information. Although these women represented more than 70% of those with interval cancers, their number was too small to pursue all of our planned analyses. Larger confirmatory studies are needed.
In conclusion, we found that women with interval cancers are most likely to initiate a visit to a health care clinician when they have 2 or more breast-related concerns. These concerns are most likely to include having a lump and a personal and family history of breast cancer. Women at highest risk for breast cancer may need closer surveillance than the general population of women. It may be reasonable to encourage them to seek care from their primary care clinicians if they develop breast symptoms, rather than taking reassurance from a negative screening mammogram.
| FOOTNOTES |
|---|
Funding support: This work was supported by UO1CA86082 of the National Cancer Institute.
Received for publication July 21, 2005. Revision received February 14, 2006. Accepted for publication March 4, 2006.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. C. Stange In This Issue: Prescribing Drugs: What Do Patients and Pharmaceutical Companies Really Want? Ann. Fam. Med, November 1, 2006; 4(6): 482 - 483. [Full Text] [PDF] |
||||
Read all TRACK Comments
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |